Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors

Authors: Luísa Pereira, Pedro Soares, Valdemar Máximo, David C Samuels

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

The presence of somatic mitochondrial DNA (mtDNA) mutations in cancer cells has been interpreted in controversial ways, ranging from random neutral accumulation of mutations, to positive selection for high pathogenicity, or conversely to purifying selection against high pathogenicity variants as occurs at the population level.

Methods

Here we evaluated the predicted pathogenicity of somatic mtDNA mutations described in cancer and compare these to the distribution of variations observed in the global human population and all possible protein variations that could occur in human mtDNA. We focus on oncocytic tumors, which are clearly associated with mitochondrial dysfunction. The protein variant pathogenicity was predicted using two computational methods, MutPred and SNPs&GO.

Results

The pathogenicity score of the somatic mtDNA variants were significantly higher in oncocytic tumors compared to non-oncocytic tumors. Variations in subunits of Complex I of the electron transfer chain were significantly more common in tumors with the oncocytic phenotype, while variations in Complex V subunits were significantly more common in non-oncocytic tumors.

Conclusions

Our results show that the somatic mtDNA mutations reported over all tumors are indistinguishable from a random selection from the set of all possible amino acid variations, and have therefore escaped the effects of purifying selection that act strongly at the population level. We show that the pathogenicity of somatic mtDNA mutations is a determining factor for the oncocytic phenotype. The opposite associations of the Complex I and Complex V variants with the oncocytic and non-oncocytic tumors implies that low mitochondrial membrane potential may play an important role in determining the oncocytic phenotype.
Appendix
Available only for authorised users
Literature
1.
Samuels DC, Carothers AD, Horton R, Chinnery PF: The power to detect disease associations with mitochondrial DNA haplogroups. Am J Hum Genet. 2006, 78 (4): 713-720. 10.1086/502682.CrossRefPubMedPubMedCentral
2.
Brandon M, Baldi P, Wallace DC: Mitochondrial mutations in cancer. Oncogene. 2006, 25 (34): 4647-4662. 10.1038/sj.onc.1209607.CrossRefPubMed
3.
Lima J, Máximo V, Soares P, Portugal R, Guimarães S, Sobrinho-Simoes M: Mitochondria and oncocytomas. Mitochondria and Cancer. Edited by: Singh K, Costello L. 2009, New York: Springer, 193-209.CrossRef
4.
Maximo V, Sobrinho-Simoes M: Hurthle cell tumours of the thyroid. A review with emphasis on mitochondrial abnormalities with clinical relevance. Virchows Arch. 2000, 437 (2): 107-115. 10.1007/s004280000219.CrossRefPubMed
5.
Gasparre G, Bonora E, Tallini G, Romeo G: Molecular features of thyroid oncocytic tumors. Mol Cell Endocrinol. 2010, 321 (1): 67-76. 10.1016/j.mce.2010.02.022.CrossRefPubMed
6.
Gasparre G, Porcelli AM, Bonora E, Pennisi LF, Toller M, Iommarini L, Ghelli A, Moretti M, Betts CM, Martinelli GN, et al: Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors. Proc Natl Acad Sci USA. 2007, 104 (21): 9001-9006. 10.1073/pnas.0703056104.CrossRefPubMedPubMedCentral
7.
Gasparre G, Hervouet E, de Laplanche E, Demont J, Pennisi LF, Colombel M, Mege-Lechevallier F, Scoazec JY, Bonora E, Smeets R, et al: Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet. 2008, 17 (7): 986-995.CrossRefPubMed
8.
Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M: Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am J Pathol. 2002, 160 (5): 1857-1865. 10.1016/S0002-9440(10)61132-7.CrossRefPubMedPubMedCentral
9.
Porcelli AM, Ghelli A, Ceccarelli C, Lang M, Cenacchi G, Capristo M, Pennisi LF, Morra I, Ciccarelli E, Melcarne A, et al: The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum Mol Genet. 2010, 19 (6): 1019-1032. 10.1093/hmg/ddp566.CrossRefPubMed
10.
Costa-Guda J, Tokura T, Roth SI, Arnold A: Mitochondrial DNA mutations in oxyphilic and chief cell parathyroid adenomas. BMC Endocr Disord. 2007, 7: 8-10.1186/1472-6823-7-8.CrossRefPubMedPubMedCentral
11.
Gasparre G, Romeo G, Rugolo M, Porcelli AM: Learning from oncocytic tumors: Why choose inefficient mitochondria?. Biochim Biophys Acta. 2011, 1807 (6): 633-642. 10.1016/j.bbabio.2010.08.006.CrossRefPubMed
12.
Mishmar D, Ruiz-Pesini E, Golik P, Macaulay V, Clark AG, Hosseini S, Brandon M, Easley K, Chen E, Brown MD, et al: Natural selection shaped regional mtDNA variation in humans. Proc Natl Acad Sci USA. 2003, 100 (1): 171-176. 10.1073/pnas.0136972100.CrossRefPubMed
13.
Kivisild T, Shen P, Wall DP, Do B, Sung R, Davis K, Passarino G, Underhill PA, Scharfe C, Torroni A, et al: The role of selection in the evolution of human mitochondrial genomes. Genetics. 2006, 172 (1): 373-387.CrossRefPubMedPubMedCentral
14.
Ingman M, Gyllensten U: Rate variation between mitochondrial domains and adaptive evolution in humans. Hum Mol Genet. 2007, 16 (19): 2281-2287. 10.1093/hmg/ddm180.CrossRefPubMed
15.
Ruiz-Pesini E, Mishmar D, Brandon M, Procaccio V, Wallace DC: Effects of purifying and adaptive selection on regional variation in human mtDNA. Science. 2004, 303 (5655): 223-226. 10.1126/science.1088434.CrossRefPubMed
16.
Pereira L, Soares P, Radivojac P, Li B, Samuels DC: Comparing phylogeny and the predicted pathogenicity of protein variations reveals equal purifying selection across the global human mtDNA diversity. Am J Hum Genet. 2011, 88 (4): 433-439. 10.1016/j.ajhg.2011.03.006.CrossRefPubMedPubMedCentral
17.
Li B, Krishnan VG, Mort ME, Xin F, Kamati KK, Cooper DN, Mooney SD, Radivojac P: Automated inference of molecular mechanisms of disease from amino acid substitutions. Bioinformatics. 2009, 25 (21): 2744-2750. 10.1093/bioinformatics/btp528.CrossRefPubMedPubMedCentral
18.
Stafford P, Chen-Quin EB: The pattern of natural selection in somatic cancer mutations of human mtDNA. J Hum Genet. 2010, 55 (9): 605-612. 10.1038/jhg.2010.76.CrossRefPubMed
19.
Coller HA, Khrapko K, Bodyak ND, Nekhaeva E, Herrero-Jimenez P, Thilly WG: High frequency of homoplasmic mitochondrial DNA mutations in human tumors can be explained without selection. Nat Genet. 2001, 28 (2): 147-150. 10.1038/88859.CrossRefPubMed
20.
21.
Zhidkov I, Livneh EA, Rubin E, Mishmar D: MtDNA mutation pattern in tumors and human evolution are shaped by similar selective constraints. Genome Res. 2009, 19 (4): 576-580. 10.1101/gr.086462.108.CrossRefPubMedPubMedCentral
22.
Palanichamy MG, Zhang YP: Potential pitfalls in MitoChip detected tumor-specific somatic mutations: a call for caution when interpreting patient data. BMC Cancer. 2010, 10: 597-10.1186/1471-2407-10-597.CrossRefPubMedPubMedCentral
23.
Zhou S, Kachhap S, Sun W, Wu G, Chuang A, Poeta L, Grumbine L, Mithani SK, Chatterjee A, Koch W, et al: Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proc Natl Acad Sci USA. 2007, 104 (18): 7540-7545. 10.1073/pnas.0610818104.CrossRefPubMedPubMedCentral
24.
Abu-Amero KK, Alzahrani AS, Zou M, Shi Y: High frequency of somatic mitochondrial DNA mutations in human thyroid carcinomas and complex I respiratory defect in thyroid cancer cell lines. Oncogene. 2005, 24 (8): 1455-1460. 10.1038/sj.onc.1208292.CrossRefPubMed
25.
Bi R, Li WL, Chen MQ, Zhu Z, Yao YG: Rapid identification of mtDNA somatic mutations in gastric cancer tissues based on the mtDNA phylogeny. Mutat Res. 2011, 709-710: 15-20.CrossRefPubMed
26.
Fendt L, Niederstatter H, Huber G, Zelger B, Dunser M, Seifarth C, Rock A, Schafer G, Klocker H, Parson W: Accumulation of mutations over the entire mitochondrial genome of breast cancer cells obtained by tissue microdissection. Breast Cancer Res Treat. 2011, 128: 327-336. 10.1007/s10549-010-1092-8.CrossRefPubMed
27.
Fliss MS, Usadel H, Caballero OL, Wu L, Buta MR, Eleff SM, Jen J, Sidransky D: Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000, 287 (5460): 2017-2019. 10.1126/science.287.5460.2017.CrossRefPubMed
28.
He L, Luo L, Proctor SJ, Middleton PG, Blakely EL, Taylor RW, Turnbull DM: Somatic mitochondrial DNA mutations in adult-onset leukaemia. Leukemia. 2003, 17 (12): 2487-2491. 10.1038/sj.leu.2403146.CrossRefPubMed
29.
Hung WY, Wu CW, Yin PH, Chang CJ, Li AF, Chi CW, Wei YH, Lee HC: Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer. Biochim Biophys Acta. 2010, 1800 (3): 264-270. 10.1016/j.bbagen.2009.06.006.CrossRefPubMed
30.
Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S: Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion. 2007, 7 (5): 347-353. 10.1016/j.mito.2007.06.003.CrossRefPubMed
31.
Kloss-Brandstatter A, Schafer G, Erhart G, Huttenhofer A, Coassin S, Seifarth C, Summerer M, Bektic J, Klocker H, Kronenberg F: Somatic mutations throughout the entire mitochondrial genome are associated with elevated PSA levels in prostate cancer patients. Am J Hum Genet. 2010, 87 (6): 802-812. 10.1016/j.ajhg.2010.11.001.CrossRefPubMedPubMedCentral
32.
Liu VW, Shi HH, Cheung AN, Chiu PM, Leung TW, Nagley P, Wong LC, Ngan HY: High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res. 2001, 61 (16): 5998-6001.PubMed
33.
Lueth M, Wronski L, Giese A, Kirschner-Schwabe R, Pietsch T, von Deimling A, Henze G, Kurtz A, Driever PH: Somatic mitochondrial mutations in pilocytic astrocytoma. Cancer Genet Cytogenet. 2009, 192 (1): 30-35. 10.1016/j.cancergencyto.2009.03.002.CrossRefPubMed
34.
Meierhofer D, Mayr JA, Fink K, Schmeller N, Kofler B, Sperl W: Mitochondrial DNA mutations in renal cell carcinomas revealed no general impact on energy metabolism. Br J Cancer. 2006, 94 (2): 268-274. 10.1038/sj.bjc.6602929.CrossRefPubMedPubMedCentral
35.
Nagy A, Wilhelm M, Sukosd F, Ljungberg B, Kovacs G: Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 2002, 35 (3): 256-260. 10.1002/gcc.10118.CrossRefPubMed
36.
Parrella P, Xiao Y, Fliss M, Sanchez-Cespedes M, Mazzarelli P, Rinaldi M, Nicol T, Gabrielson E, Cuomo C, Cohen D, et al: Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res. 2001, 61 (20): 7623-7626.PubMed
37.
Petros JA, Baumann AK, Ruiz-Pesini E, Amin MB, Sun CQ, Hall J, Lim S, Issa MM, Flanders WD, Hosseini SH, et al: mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci USA. 2005, 102 (3): 719-724. 10.1073/pnas.0408894102.CrossRefPubMedPubMedCentral
38.
Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, Trush MA, Kinzler KW, Vogelstein B: Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998, 20 (3): 291-293. 10.1038/3108.CrossRefPubMed
39.
Shen L, Wei J, Chen T, He J, Qu J, He X, Jiang L, Qu Y, Fang H, Chen G, et al: Evaluating mitochondrial DNA in patients with breast cancer and benign breast disease. J Cancer Res Clin Oncol. 2011, 137 (4): 669-675. 10.1007/s00432-010-0912-x.CrossRefPubMed
40.
Tan DJ, Bai RK, Wong LJ: Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002, 62 (4): 972-976.PubMed
41.
Tan DJ, Chang J, Chen WL, Agress LJ, Yeh KT, Wang B, Wong LJ: Novel heteroplasmic frameshift and missense somatic mitochondrial DNA mutations in oral cancer of betel quid chewers. Genes Chromosomes Cancer. 2003, 37 (2): 186-194. 10.1002/gcc.10217.CrossRefPubMed
42.
Tan DJ, Chang J, Liu LL, Bai RK, Wang YF, Yeh KT, Wong LJ: Significance of somatic mutations and content alteration of mitochondrial DNA in esophageal cancer. BMC Cancer. 2006, 6: 93-10.1186/1471-2407-6-93.CrossRefPubMedPubMedCentral
43.
Vivekanandan P, Daniel H, Yeh MM, Torbenson M: Mitochondrial mutations in hepatocellular carcinomas and fibrolamellar carcinomas. Mod Pathol. 2010, 23 (6): 790-798. 10.1038/modpathol.2010.51.CrossRefPubMedPubMedCentral
44.
Wong LJ, Lueth M, Li XN, Lau CC, Vogel H: Detection of mitochondrial DNA mutations in the tumor and cerebrospinal fluid of medulloblastoma patients. Cancer Res. 2003, 63 (14): 3866-3871.PubMed
45.
Yeh JJ, Lunetta KL, van Orsouw NJ, Moore FD, Mutter GL, Vijg J, Dahia PL, Eng C: Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential mtDNA sequence variants in cases with thyroid tumours. Oncogene. 2000, 19 (16): 2060-2066. 10.1038/sj.onc.1203537.CrossRefPubMed
46.
Yin PH, Wu CC, Lin JC, Chi CW, Wei YH, Lee HC: Somatic mutations of mitochondrial genome in hepatocellular carcinoma. Mitochondrion. 2010, 10 (2): 174-182. 10.1016/j.mito.2009.12.147.CrossRefPubMed
47.
Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis. 2005, 26 (1): 145-152.CrossRefPubMed
48.
Pereira L, Freitas F, Fernandes V, Pereira JB, Costa MD, Costa S, Maximo V, Macaulay V, Rocha R, Samuels DC: The diversity present in 5140 human mitochondrial genomes. Am J Hum Genet. 2009, 84 (5): 628-640. 10.1016/j.ajhg.2009.04.013.CrossRefPubMedPubMedCentral
49.
van Oven M, Kayser M: Updated comprehensive phylogenetic tree of global human mitochondrial DNA variation. Hum Mutat. 2009, 30 (2): E386-394. 10.1002/humu.20921.CrossRefPubMed
50.
Kloss-Brandstatter A, Pacher D, Schonherr S, Weissensteiner H, Binna R, Specht G, Kronenberg F: HaploGrep: a fast and reliable algorithm for automatic classification of mitochondrial DNA haplogroups. Hum Mutat. 2011, 32 (1): 25-32. 10.1002/humu.21382.CrossRefPubMed
51.
Salas A, Yao YG, Macaulay V, Vega A, Carracedo A, Bandelt HJ: A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med. 2005, 2 (11): e296-10.1371/journal.pmed.0020296.CrossRefPubMedPubMedCentral
52.
Bandelt HJ, Salas A: Contamination and sample mix-up can best explain some patterns of mtDNA instabilities in buccal cells and oral squamous cell carcinoma. BMC Cancer. 2009, 9: 113-10.1186/1471-2407-9-113.CrossRefPubMedPubMedCentral
53.
Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N: Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 1999, 23 (2): 147-147. 10.1038/13779.CrossRefPubMed
54.
Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R: Functional annotations improve the predictive score of human disease-related mutations in proteins. Hum Mutat. 2009, 30 (8): 1237-1244. 10.1002/humu.21047.CrossRefPubMed
55.
Thusberg J, Olatubosun A, Vihinen M: Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat. 2011, 32 (4): 358-368. 10.1002/humu.21445.CrossRefPubMed
56.
Mueller-Hoecker J, Aust D, Napiwotzky J, Muenscher C, Link TA, Seibel P, Schneeweiss SG, Kadenbach B: Defects of the respiratory chain in oxyphil and chief cells of the normal parathyroid and in hyperfunction. Human Pathology. 1996, 27 (6): 532-541. 10.1016/S0046-8177(96)90158-6.CrossRef
57.
Sobrinho-Simoes M, Maximo V, Castro IV, Fonseca E, Soares P, Garcia-Rostan G, Oliveira MC: Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int J Surg Pathol. 2005, 13 (1): 29-35. 10.1177/106689690501300104.CrossRefPubMed
58.
Gasparre G, Iommarini L, Porcelli AM, Lang M, Ferri GG, Kurelac I, Zuntini R, Mariani E, Pennisi LF, Pasquini E, et al: An inherited mitochondrial DNA disruptive mutation shifts to homoplasmy in oncocytic tumor cells. Hum Mutat. 2009, 30 (3): 391-396. 10.1002/humu.20870.CrossRefPubMed
59.
Gillies RJ, Gatenby RA: Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis?. J Bioenerg Biomembr. 2007, 39 (3): 251-257. 10.1007/s10863-007-9085-y.CrossRefPubMed
60.
Gillies RJ, Gatenby RA: Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007, 26 (2): 311-317. 10.1007/s10555-007-9065-z.CrossRefPubMed
61.
Shidara Y, Yamagata K, Kanamori T, Nakano K, Kwong JQ, Manfredi G, Oda H, Ohta S: Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res. 2005, 65 (5): 1655-1663. 10.1158/0008-5472.CAN-04-2012.CrossRefPubMed
Metadata
Title
Somatic mitochondrial DNA mutations in cancer escape purifying selection and high pathogenicity mutations lead to the oncocytic phenotype: pathogenicity analysis of reported somatic mtDNA mutations in tumors
Authors
Luísa Pereira
Pedro Soares
Valdemar Máximo
David C Samuels
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-53

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Correlation between Duffy blood group phenotype and breast cancer incidence

Research article

The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

Research article

Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers

Research article

Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes

Research article

Opposing function of MYBBP1A in proliferation and migration of head and neck squamous cell carcinoma cells

Research article

Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits